Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts-Reference-Cited by-同舟云学术

Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts

Published:2010-08-31 Issue:2 Volume:128 Page:381-390
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Nukatsuka Mamoru,Saito Hitoshi,Nakagawa Fumio,Abe Masaaki,Uchida Junji,Shibata Jiro,Matsuo Ken-ichi,Noguchi Shinzaburo,Kiniwa Mamoru

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-010-1141-3.pdf

Reference43 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467

2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

3. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK, Breast Cancer Intergroup of North America (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:2055–2063

4. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Cancer and Leukemia Group B (CALGB) Investigators (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496–1506

5. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A (2009) Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 20:628–635

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of metronomic cyclophosphamide combined with abiraterone and dexamethasone in heavily pretreated metastatic castration-resistant prostate cancer: A retrospective, real-world study;Asian Journal of Surgery;2024-08

2. Chemotherapy combined with endocrine therapy: Old wine in a new bottle?;Clinical Breast Cancer;2024-08

3. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer;Current Oncology;2023-06-24

4. Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer;Oncology Research and Treatment;2022

5. Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?;Expert Review of Anticancer Therapy;2020-06-30